ABIT:F:F-AXA IM ACT Biodiversity Equity UCITS ETF - USD Acc EUR (EUR)

ETF | Others |

Last Closing

USD 12.154

Change

-0.20 (-1.60)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-18 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.11 (+0.41%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.23 (+0.45%)

USD 114.95B
SXR8:F iShares Core S&P 500 UCITS ETF..

-1.88 (-0.32%)

USD 98.13B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 91.82B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.05 (+0.30%)

USD 54.47B
VUAA:F Vanguard S&P 500 UCITS Acc

N/A

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

-0.01 (0.00%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+1.45 (+0.62%)

USD 50.58B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 40.89B
0ZC:F Zscaler Inc

+2.38 (+1.25%)

USD 37.92B

ETFs Containing ABIT:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.15% 70% C- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.15% 68% D+ 63% D
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike